Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 33,205 matching trials from the live ClinicalTrials.gov search.
Conditions
Overweight, Obesity
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
8 Years to 18 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
34
States / cities
Escondido, California • Hollywood, Florida • Jacksonville, Florida + 29 more
Completed Phase 1 Interventional Accepts healthy volunteers

Oral Remimazolam With and Without Alcohol in Healthy Female Subjects

NCT04113343
Conditions
Safety Issues
Interventions
Remimazolam, Alcohol
Drug · Other
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
21 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Bacterial Infection
Interventions
MBN-101, Placebo
Drug · Other
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ACE-536 in Healthy Postmenopausal Women

NCT01432717
Conditions
Anemia
Interventions
ACE-536, Placebo
Biological · Other
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
45 Years to 75 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Migraine Headache, Episodic
Interventions
neuromodulation for episodic migraine headache
Device
Lead sponsor
Scion NeuroStim
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
San Diego, California • Ann Arbor, Michigan • Chapel Hill, North Carolina + 2 more
Not listed Phase 1 Interventional Accepts healthy volunteers

Effect of Gene Variants on Dopamine Receptor Natriuretic Responses

NCT00592150
Conditions
Hypertension
Interventions
fenoldopam, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Hereditary Angioedema
Interventions
CSL312, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more
Conditions
Ischemic Heart Failure
Interventions
JVS-100 15 mg dose Injection, Placebo Injection, JVS-100 30 mg dose injection
Biological
Lead sponsor
Juventas Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
16
States / cities
Birmingham, Alabama • Gainesville, Florida • Tampa, Florida + 12 more
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine, Radiation
Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Dallas, Texas + 2 more
Conditions
HIV Infections
Interventions
DNA CON-S env, IHV01, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity

NCT02542943
Conditions
Dentin Sensitivity
Interventions
Experimental Oral Rinse 1, Experimental Oral Rinse 2, Placebo Oral Rinse, Standard fluoride toothpaste
Device · Other · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Multiple Sclerosis, Optic Nerve, Neuritis
Interventions
Nerispirdine, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Dermatitis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Alprostadil, Placebo
Drug · Other
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Trial for Botox Urinary Incontinence

NCT00178191
Conditions
Urinary Incontinence
Interventions
Bladder diary, Questionnaires, Urodynamics, Pad weight
Other · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, New York
Conditions
Cardiac Toxicity
Interventions
Moxifloxacin
Drug
Lead sponsor
Haiyan Li
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Conditions
Irritable Bowel Syndrome, Fibromyalgia
Interventions
Glutamate additive-free diet, Placebo diet
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 14 more
Conditions
HIV Infections
Interventions
Chloroquine, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Conditions
Mild Persistent Asthma, Uncomplicated
Interventions
Nadolol, Placebo
Drug
Lead sponsor
Invion, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
3
States / cities
St Louis, Missouri • Durham, North Carolina • Houston, Texas
Conditions
Asthma
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Bakersfield, California • Huntington Beach, California • Los Angeles, California + 6 more
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota